| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/13/1997 | WO1997005250A2 Receptor ligand vegf-c |
| 02/13/1997 | WO1997005249A2 Extension of a protein-protein interaction surface to inactivate the function of a cellular protein |
| 02/13/1997 | WO1997005244A1 Mocarhagin, a cobra venom protease, and therapeutic uses thereof |
| 02/13/1997 | WO1997005242A1 Novel replication competent human immunodeficiency virus type 2 (hiv-2) proviral clone designated hiv-2kr |
| 02/13/1997 | WO1997005241A2 Methods and compositions for identifying morphogen analogs |
| 02/13/1997 | WO1997005239A1 Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease |
| 02/13/1997 | WO1997005185A2 Multiblock biodegradable hydrogels for use as controlled release agents for drugs delivery and tissue treatment agents |
| 02/13/1997 | WO1997005169A1 Ha-2 antigenic peptide |
| 02/13/1997 | WO1997005168A1 The h-y antigen |
| 02/13/1997 | WO1997005167A1 Somatostatin-analogous cyclic peptides with inhibitory activity on growth hormone |
| 02/13/1997 | WO1997005166A1 Transforming growth factor beta crystals |
| 02/13/1997 | WO1997005163A1 Cyclic peptide anti-fungal agents |
| 02/13/1997 | WO1997005161A1 Boronic acid derivatives |
| 02/13/1997 | WO1997005160A1 Bicyclic lactam derivatives as thrombin inhibitors |
| 02/13/1997 | WO1997005158A1 Compositions, treatments, and diagnostics for schistosomiasis and related diseases |
| 02/13/1997 | WO1997005157A1 Gene encoding the human homolog of mad2 |
| 02/13/1997 | WO1997005108A1 Penicillaminamide derivatives |
| 02/13/1997 | WO1997005107A1 Serine derivatives |
| 02/13/1997 | WO1997004810A1 Dax-1 protein, methods for production and use thereof |
| 02/13/1997 | WO1997004807A1 Methods for treatment of allergic asthma |
| 02/13/1997 | WO1997004806A1 Remedy for neurological disorders |
| 02/13/1997 | WO1997004805A1 Genetically engineered chimeric viruses for the treatment of diseases associated with viral transactivators |
| 02/13/1997 | WO1997004801A1 Stabile isotonic lyophilized protein formulation |
| 02/13/1997 | WO1997004800A1 Treatment of nocturnal polyuria using an ace inhibitor in combination with a diuretic |
| 02/13/1997 | WO1997004799A1 Remedy for bone diseases |
| 02/13/1997 | WO1997004797A1 Use of neuronal calcium channel blockers for the manufacture of a medicament for the treatment of psychoses, schizophrenia and cocaine or amphetamine addiction |
| 02/13/1997 | WO1997004796A1 Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations |
| 02/13/1997 | WO1997004795A2 Pharmaceutical compositions containing cyclosporin or other peptide substances |
| 02/13/1997 | WO1997004794A1 Modulators of expression and function of lrp in alzheimer's disease |
| 02/13/1997 | WO1997004792A1 Bowman-birk inhibitor compositions for treatment of imflammatory disease |
| 02/13/1997 | WO1997004748A2 Enhanced artificial viral envelopes for cellular delivery of therapeutic substances |
| 02/13/1997 | WO1997004720A1 The use of autologous dermal fibroblasts for the repair of skin and soft tissue defects |
| 02/13/1997 | WO1997004658A1 Herpes simplex virus 1 entry into cells mediated by a novel member of the tnf/ngf receptor family |
| 02/13/1997 | WO1997004647A1 Methods of detecting duplication mutated fibrillin-1 gene and compositions and methods of using the same |
| 02/13/1997 | WO1996035774A3 Angiostatin fragments and aggregate angiostatin and methods of use |
| 02/13/1997 | WO1996034969A3 Gene therapy using replication competent targeted adenoviral vectors |
| 02/13/1997 | WO1996018732A3 Sequence-specific inhibition of dna synthesis by triplex-forming oligonucleotides |
| 02/13/1997 | WO1996017933A3 Dna encoding a cell growth inhibiting factor and its product |
| 02/13/1997 | WO1996013583A3 Targeted hetero-association of recombinant proteins to multi-functional complexes |
| 02/13/1997 | WO1996002572A3 Antigenic polypeptide sequence of factor viii, fragments and/or epitopes thereof |
| 02/13/1997 | WO1995027071A3 An adenovirus supervector system |
| 02/13/1997 | DE19529223A1 Verwendung von Plasminogenaktivatoren zum lokalen Knochenaufbau Use of plasminogen activators to the local bone formation |
| 02/13/1997 | CA2745743A1 Stabile isotonic lyophilized protein formulation |
| 02/13/1997 | CA2246561A1 Modulators of expression and function of lrp in alzheimer's disease |
| 02/13/1997 | CA2228378A1 Cytidine deaminase cdna as a positive selectable marker for gene transfer, gene therapy and protein synthesis |
| 02/13/1997 | CA2228374A1 Extension of a protein-protein interaction surface to inactivate the function of a cellular protein |
| 02/13/1997 | CA2228248A1 Receptor ligand vegf-c |
| 02/13/1997 | CA2228118A1 Multiblock biodegradable hydrogels for use as controlled release agents for drugs delivery and tissue treatments agents |
| 02/13/1997 | CA2227980A1 Somatostatin-analogous cyclic peptides with inhibitory activity on growth hormone |
| 02/13/1997 | CA2227972A1 Mocarhagin, a cobra venom protease and therapeutic uses thereof |
| 02/13/1997 | CA2227871A1 Mucosal delivery of polynucleotides |
| 02/13/1997 | CA2227769A1 Methods and compositions for identifying morphogen analogs |
| 02/13/1997 | CA2227694A1 Methods and compositions for identifying morphogen analogs |
| 02/13/1997 | CA2227364A1 Cyclic peptide anti-fungal agents |
| 02/13/1997 | CA2227327A1 Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease |
| 02/13/1997 | CA2226860A1 Novel replication competent human immunodeficiency virus type 2 (hiv-2) proviral clone designated hiv-2kr |
| 02/13/1997 | CA2226624A1 Methods for treatment of allergic asthma |
| 02/13/1997 | CA2224909A1 Ha-2 antigenic peptide |
| 02/13/1997 | CA2224894A1 The h-y antigen |
| 02/13/1997 | CA2223968A1 Bowman-birk inhibitor compositions for treatment of inflammatory disease |
| 02/13/1997 | CA2200879A1 Drug for treating bone disorders |
| 02/13/1997 | CA2200606A1 Chimeric receptors and methods for identifying compounds active at metabotropic glutamate receptors and the use of such compounds in the treatment of neurological disorders and diseases |
| 02/12/1997 | EP0758021A2 Method for determining the therapeutic activity of metalloproteinase inhibitor compounds, new inhibitor compounds, and the therapeutic use thereof |
| 02/12/1997 | EP0757994A1 Tcf mutant |
| 02/12/1997 | EP0757993A1 Preventive for circulatory diseases |
| 02/12/1997 | EP0757719A1 $g(a)-1-ANTICHYMOTRYPSIN ANALOGUES HAVING CHYMASE INHIBITING ACTIVITY |
| 02/12/1997 | EP0757718A1 Methods of use of uncoated gel particles |
| 02/12/1997 | EP0757717A1 Papillomavirus vaccines |
| 02/12/1997 | EP0757716A1 Dna encoding bradykinin b 1? receptor |
| 02/12/1997 | EP0757697A1 Use of agents which block intercellular adhesion molecule/receptor interaction in the treatment of respiratory viral infection |
| 02/12/1997 | EP0757696A1 Human sperm diagnostic |
| 02/12/1997 | EP0757694A1 Thioether compounds for use in preparing bifunctional chelating agents for therapeutic radiopharmaceuticals |
| 02/12/1997 | EP0757689A1 Porphocyanine and cnc-expanded porphyrins |
| 02/12/1997 | EP0757559A1 Composition for delivery of toxic radioisotopes to the cell nucleus and use |
| 02/12/1997 | EP0757557A1 Methods for inducing t cell tolerance to a tissue or organ graft |
| 02/12/1997 | EP0564588B1 Hexapeptide anaphylatoxin-receptor ligands |
| 02/12/1997 | EP0440777B1 Brain derived neurotrophic factor |
| 02/12/1997 | CN1142855A Humanized antibodies and uses thereof |
| 02/12/1997 | CN1142854A C5a receptor antagonists having substantially no agonist activity |
| 02/12/1997 | CN1142832A CS-1 peptidomimetics, compositions and methods of using the same |
| 02/12/1997 | CN1142831A Novel 2-substituted indane-2-mercaploacetylamide disulfide derivatives useful as inhibitors of enkephalinase and ace |
| 02/12/1997 | CN1142830A Macrocyclic difluorostatone derivatives useful as antiviral agents |
| 02/12/1997 | CN1142826A Novel mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase and ace |
| 02/12/1997 | CN1142816A Crystalline, polymorphic form of (S,S,S)-n-(1-|2-carboxy-3-(n2-mesyllysylamino)propyl¨-1-cyclopenlylcarbonyl)tyrosine |
| 02/12/1997 | CN1142776A Hirudin conjugates from hirudin and lipophilic compounds |
| 02/12/1997 | CN1142775A Preparation and use of immunoconjugates |
| 02/12/1997 | CN1142772A Parathyroid hormone formulation |
| 02/12/1997 | CN1142771A Lyophilized stem cell factor formulations |
| 02/12/1997 | CN1142770A Composition and methods to improve neural outcome |
| 02/12/1997 | CN1142505A Anti-idiotypic antibodies which induce immune response against epidermal growth factor receptor |
| 02/12/1997 | CN1142504A Fluoridated micellar casein |
| 02/12/1997 | CA2183020A1 Activated immunoglobulin |
| 02/11/1997 | US5602306 Transgenic pig expressing human hemoglobin |
| 02/11/1997 | US5602275 May be used to accelerate recovery from neutropenia accompanying radio- or chemotherapy, bone marrow transplantation or infections |
| 02/11/1997 | US5602253 Peptides derivatives |
| 02/11/1997 | US5602233 Activation and deactivation |
| 02/11/1997 | US5602232 Reacting interferon with supersaturated solution of metal acetate |
| 02/11/1997 | US5602230 Peptide inhibitors of selectin binding |
| 02/11/1997 | US5602229 Pentapeptide antibiotics |
| 02/11/1997 | US5602175 Retroviral protease inhibitors |